RET fusion positive non-small cell lung cancer
Conditions
Interventions
Sorafenib is given a dose of 400mg/body twice daily.
Sponsors
Japanese Foundation for Cancer Research Cancer Institute Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)Histologically or cytologically confirned advanced non-small-cell lung cancer 2)RET fusion positive non-small-cell lung cancer 3)One or more previous chemotherapy regimens 4)Subjects must be off prior chemotherapy at least 3 weeks prior to study entry. 5)Subjects who received radiotherapy to chest must have completed treatment at least 12 weeks prior to study entry. 6)Subjects who received radiotherapy to any site without chest must have completed treatment at least 2 weeks prior to study entry. 7)Subjects who received intrapleural therapy for malignant pleural effusions must have completed treatment at least 2 weeks prior to study entry. 8)ECOG Performance status 0-2 9)more than 20 years old 10)Adequate organ function 11)Life expectancy at least 3 months 12)Signed informed consent
Exclusion criteria
Exclusion criteria: 1)Serious complications 2)Brain metastases need raidotherapy 3)Subjects with interstitial pneumonia or pulmonary fibrosis by chest X-ray 4)Patients who can not take orally. 5)Patients who have serious hypersensitivity reaction. 6)Patients who receive prohibited treatments. 7)Pregnancy, breast feeding or wish of future bearing 8)Concurrent use of steriod therapy except for topical or inhaled 9)Active infectious disease 10)Pleural effusion, peritoneal fluid, and pericardial fluid need drainage therapy 11)Patients whose participation in the trial is judged to be inappropriate by the attending doctor
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| feasibility | — |
Countries
Japan
Contacts
Public ContactAtsushi Horiike
Japanese Foundation for Cancer Research Cancer Institute Hospital Department of Thoracic Medical Oncology
Outcome results
None listed